← Back to Search

Buzzy(R) for Breast Cancer

Phase 3
Waitlist Available
Led By Heather B Neuman, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
greater than or equal to 18 years of age
biopsy proven breast cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed after last participant off study (up to 12.5 months)
Awards & highlights

Study Summary

Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer

Eligible Conditions
  • Breast Cancer
  • Sentinel Lymph Node

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed after last participant off study (up to 12.5 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed after last participant off study (up to 12.5 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Median Post-Procedural Pain Score
Secondary outcome measures
Degree of Anxiety During the Injection as Measured by Number of Participants Moderately Anxious
Degree of Participant Satisfaction With Attention Paid to Complaints as Reported by Number of Participants Who Report Satisfied or Very Satisfied
Degree of Participant Satisfaction With Care Provided During Injection as Reported by Number of Participants Who Report Satisfied or Very Satisfied
+10 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Lidocaine Patch and Buzzy(R)Experimental Treatment3 Interventions
A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
Group II: Lidocaine PatchExperimental Treatment1 Intervention
A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
Group III: Buzzy(R)Experimental Treatment2 Interventions
A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
Group IV: Ice PackActive Control1 Intervention
Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lidocaine patch
2021
Completed Phase 3
~350
Buzzy(R)
2021
Completed Phase 3
~170

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,479 Total Patients Enrolled
938 Trials studying Breast Cancer
1,543,166 Patients Enrolled for Breast Cancer
University of Wisconsin, MadisonLead Sponsor
1,176 Previous Clinical Trials
3,011,839 Total Patients Enrolled
35 Trials studying Breast Cancer
38,352 Patients Enrolled for Breast Cancer
Heather B Neuman, MDPrincipal InvestigatorUniversity of Wisconsin Madison School of Medicine and Public Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~43 spots leftby Mar 2025